Affiliation:
1. Department of Microbiology and Laboratory Medical Immunology, Medical University of Lodz, ul. Pomorska 251/C5, 92-213 Lodz, Poland
2. Medical Microbiology Laboratory, Central Teaching Hospital of Medical University of Lodz, ul. Pomorska 251/C5, 92-213 Lodz, Poland
Abstract
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam. Unfortunately, the latter may be simultaneously inactivated by serine β-lactamases. The most dangerous known MBL is New Delhi Metallo-β-lactamase (NDM). This study aimed to test the in vitro susceptibility to aztreonam in combination with novel β-lactamase inhibitors (avibactam, relebactam, and vaborbactam) in clinical strains of Enterobacterales NDM which is resistant to aztreonam. We investigated 21 NDM isolates—including Klebsiella pneumoniae, Escherichia coli, and Citrobacter freundii—which are simultaneously resistant to aztreonam, ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam. MICs for aztreonam combinations with novel inhibitors were determined using the gradient strip superposition method. The most effective combination was aztreonam/avibactam, active in 80.95% strains, while combinations with relebactam and vaborbactam were effective in 61.90% and 47.62%, respectively. In three studied strains, none of the studied inhibitors restored aztreonam susceptibility. Aztreonam/avibactam has the most significant antimicrobial potential for NDM isolates. However, combinations with other inhibitors should not be rejected in advance because we identified strain susceptible only to tested combinations with inhibitors other than avibactam. Standardization committees should, as soon as possible, develop official methodology for antimicrobial susceptibility testing for aztreonam with β-lactamase inhibitors.
Reference23 articles.
1. Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629–655.
2. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis;Tacconelli;Lancet Infect. Dis.,2018
3. KORLD (2023, November 02). Dane Krajowego Ośrodka Referencyjnego ds. Lekowrażliwości Drobnoustrojów (KORLD), Dotyczące Pałeczek Enterobacterales Wytwarzających Karbapenemazy NDM, KPC, VIM i OXA-48 na Terenie Polski w Latach 2006–2018, Available online: https://korld.nil.gov.pl/pdf/Raport%20KORLD%202019_EL_2.pdf.
4. Brauncajs, M., Bielec, F., Macieja, A., and Pastuszak-Lewandoska, D. (2022). Carbapenem-Resistant Gram-Negative Fermenting and Non-Fermenting Rods Isolated from Hospital Patients in Poland-What Are They Susceptible to?. Biomedicines, 10.
5. Hammoudi Halat, D., and Ayoub Moubareck, C. (2020). The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria. Antibiotics, 9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献